Dataset opportunity
Med X Press — 检验报告数据集机会
Med X Press 持有的中等检验报告数据集，可用于文档智能和缺陷检测。
Score
69.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球智能文档处理市场在 2025 年的估值为 104.1 亿美元，预计在 2026-2034 年期间的复合年增长率为 26.8%。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
检验报告数据集
Modality
文档
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — GDPR 敏感（个人身份信息审查）
Buyer persona
文档 AI / IDP 供应商
Med X Press 持有一个专门的文档模态数据集，侧重于制药物流，包括 `inspection_records`（检验记录）、监管文件和相关的 `transaction_data`（交易数据）。此检验报告数据集非常适合训练文档智能模型，以自动化从复杂、受监管的文档中提取、分类和验证合规性，并附带 `iot_data`（物联网数据）提供进一步的上下文完整性。
全球智能文档处理市场在 2025 年的估值为 104.1 亿美元，预计将以 26.8% 的复合年增长率增长，这表明对此类数据有巨大的需求。虽然访问涉及与客户共享数据所有权以及在制药法下处于高度监管的环境，但该数据集的稀有性和在如此高增长市场中的适用性为旨在引领医疗保健自动化领域的买家提供了引人注目的价值主张。⚠ 尽职调查（有价值的数据，可协商的访问权限）：数据所有权与制药客户共享特定产品流；高度监管的环境（麻醉品、制药法 § 47.3）需要严格遵守；SK Pharma Group 最近的收购可能会集中决策。· 公司：SK Pharma Group 的子公司。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Med X Press 拥有其高度监管的制药物流运营所产生的检验报告的专有数据集。对于寻求在复杂的、真实的制药文档上训练模型的文档 AI 和 IDP 供应商来说，这是一个高价值资产。在一个预计复合年增长率为 26.8% 的市场中，这个稀有的数据集通过实现医疗保健供应链的文档智能自动化，提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity100
主导的“检验记录”，医疗保健行业，4 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity94
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value94
适用于文档智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求异常高，这得益于智能文档处理市场 26.8% 的快速复合年增长率，而此类受监管的文档数据是关键的培训资产。
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，SK Pharma Group 的子公司
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 种证据类型，4 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
SK Pharma Group 的子公司
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 个数据胃口信号（0 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Med X Press 是一个理想的目标，作为一家制药物流领域由所有者管理的تن中小企业，其核心业务（运输、储存和处理麻醉品等敏感货物）产生了宝贵但未被充分利用的运营数据。问题：该公司最近被 SK Pharma Group 收购，这可能会改变其中小企业地位或未来的数据策略，尽管目前据称其运营数据...
- Deep Qualification80
⚠ 需要审查 — Med X Press 是一家专业的制药物流服务提供商，使其成为数据持有者。假设的“检验报告数据集”与其核心业务高度一致，但数据是代表客户生成的，这使得所有权混合，并且转售权受到监管和合同的高度限制。[许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Regulatory records
该文本证实了持有者生成与制药序列化和防伪措施相关的文档，这对于训练人工智能模型进行供应链合规性和安全性至关重要。
IoT / sensor data
这表明存在来自温控仓库的时间序列数据，为冷链物流和质量保证文件提供了重要背景。
Inspection reports
这是对注射器、药瓶甚至麻醉品等敏感产品的目视检查报告的直接证据，代表了任何高级文档处理模型的核心、高价值文档类型。
Transaction data
这些表格数据证明了合法合规的制药运输的交易记录的存在，这对于训练模型处理受特定药品法管辖的发票和提货单至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Med X Press Inspection Reports — a Moderate inspection reports dataset (Document modality) in the healthcare domain. Primary AI use-case: Document Intelligence. Market signal: Global Intelligent Document Processing market was valued at USD 10.41 billion in 2025, projected to grow at a CAGR of 26.8% (2026-2034) (source: Fortune Business Insights).. Investment score 69.8/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Eco Stor — 维护日志数据集机会
View opportunity →医疗保健Icentia — 医学影像数据集机会
View opportunity →工业Powin — 工业运营数据集机会
View opportunity →